help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on May 5, 2008, doi:10.1165/rcmb.2007-0385OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2007-0385OCv1
39/4/490    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griesenbach, U.
Right arrow Articles by Alton, E. W. F. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griesenbach, U.
Right arrow Articles by Alton, E. W. F. W.
American Journal of Respiratory Cell and Molecular Biology. Vol. 39, pp. 490-496, 2008
© 2008 American Thoracic Society
DOI: 10.1165/rcmb.2007-0385OC

Validation of Nasal Potential Difference Measurements in Gut-Corrected CF Knockout Mice

Uta Griesenbach1,*, Stephen N. Smith1,*, Raymond Farley1, Charanjit Singh1 and Eric W. F. W. Alton1

1 Department of Gene Therapy, Faculty of Medicine at the National Heart and Lung Institute, Imperial College London, London, United Kingdom; and The UK Cystic Fibrosis Gene Therapy Consortium

Correspondence and requests for reprints should be addressed to Dr. Uta Griesenbach, Department of Gene Therapy, Imperial College London, Manresa Road, London SW3 6LR, UK. E-mail: u.griesenbach{at}imperial.ac.uk

Attempts at correcting the nasal potential difference (PD) in cystic fibrosis (CF) mice have long been used in preclinical gene and small molecule therapy development. However, in general, CF mice suffer from intestinal disease, are runted, and have high mortality rates; they are therefore difficult to work with, especially if large numbers are required. Because of this, large-scale PD studies in CF mice have not been performed. Working with CF mice has become substantially easier after the generation of the gut-corrected CF-knockout mouse. Fatty acid–binding promoter (FABp)-mediated expression of CFTR in the gut, but not the airways, prevents the intestinal disease of the CF knockout mouse. This model has given us the unique opportunity to systematically study PDs in large numbers of CF mice. The nose, but not the lungs, of these animals mimic the bioelectric defect seen in humans. We have therefore assessed the bioelectrics of the respiratory epithelium comparing FABp-CF and wild-type mice. The large body of data gathered in CF and wild-type mice allowed us, for the first time, to establish power calculations that should inform sample sizes required in gene and small molecule therapy development. In addition, we address the important issues of intra-animal variability as well as intra- and inter-operator variability for scoring the traces, and the effect of age and sex on nasal PD in CF mice. These data should allow a more informed use of CF animals in future studies.

Key Words: cystic fibrosis • nasal potential difference • CF mice • gut-corrected




This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
B. R. Grubb, T. D. Rogers, R. C. Boucher, and L. E. Ostrowski
Ion transport across CF and normal murine olfactory and ciliated epithelium
Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1301 - C1309.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2008 American Thoracic Society.
  Tobacco